## **Listing of Claims:**

1. (Currently Amended) Compounds A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (I) or (Ia), and/or a pharmaceutically acceptable acid addition salt thereof,

$$R_{4}$$
 $R_{3}$ 
 $R_{4}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{4}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{7}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{7}$ 
 $R_{8}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{7}$ 
 $R_{8}$ 
 $R_{8}$ 
 $R_{8}$ 
 $R_{8}$ 

in which the substituents have the following significance:

 $R_1$ :  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkenyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ;  $C_7$ - $C_{16}$ -arylalkyl where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkinyl;

 $R_2$ :  $C_4$ - $C_6$ -alkyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ; [[ $C_7$ - $C_{16}$ -arylalkyl]]  $C_8$ ,  $C_9$ ,  $C_{10}$ ,  $C_{11}$ ,  $C_{12}$ ,  $C_{13}$ ,  $C_{14}$ ,  $C_{15}$ , or

3

 $\underline{C_{16}}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl; [[ $C_8$ - $C_{16}$ -arylalkenyl]]  $\underline{C_8}$ ,  $\underline{C_{10}}$ ,  $\underline{C_{11}}$ ,  $\underline{C_{12}}$ ,  $\underline{C_{13}}$ ,  $\underline{C_{14}}$ ,  $\underline{C_{15}}$  or  $\underline{C_{16}}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkenyl;  $C_3$ - $C_6$ -alkenyl;  $C_9$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_3$ - $C_6$ -alkenyl;  $C_9$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_3$ - $C_6$ -alkinyl;

 $R_3$ : hydrogen,  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl; alkoxyalkyl, where alkoxy is  $C_1$ - $C_6$ -alkoxy and alkyl is  $C_1$ - $C_6$ -alkyl;  $CO_2(C_1$ - $C_6$ -alkyl);  $CO_2H$ ;  $CH_2OH$ .

R<sub>4</sub>: hydrogen; hydroxy;  $C_1$ -C<sub>6</sub>-alkyloxy;  $C_2$ -C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is  $C_1$ -C<sub>4</sub> alkyloxy and alkoxy is  $C_1$ -C<sub>6</sub>-alkyloxy;  $C_2$ -C<sub>6</sub>-alkenyloxy;  $C_2$ -C<sub>6</sub>-alkinyloxy;  $C_3$ -C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is  $C_1$ -C<sub>6</sub> alkyl;  $C_4$ -C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is  $C_2$ -C<sub>6</sub> alkenyl;  $C_4$ -C<sub>16</sub>-(cyclical saturated group)alkinyloxy where alkinyl is  $C_2$ -C<sub>6</sub> alkinyl;  $C_7$ -C<sub>16</sub>-arylalkyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkyl is  $C_1$ -C<sub>6</sub>-alkyl;  $C_8$ -C<sub>16</sub>-arylalkenyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkenyl is  $C_2$ -C<sub>6</sub>-alkenyl;  $C_8$ -C<sub>16</sub>-arylalkinyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkinyl is  $C_2$ -C<sub>6</sub>-alkinoyloxy;  $C_3$ -C<sub>6</sub>-alkinoyloxy;  $C_7$ -C<sub>16</sub>-arylalkanoyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkanoyloxy is  $C_2$ -C<sub>6</sub>-alkanoyloxy;  $C_9$ -C<sub>16</sub>-arylalkenoyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkanoyloxy is  $C_3$ -C<sub>6</sub>-alkenoyloxy;  $C_9$ -C<sub>16</sub>-arylalkinoyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkanoyloxy is  $C_3$ -C<sub>6</sub>-alkenoyloxy;  $C_9$ -C<sub>16</sub>-arylalkinoyloxy, where aryl is  $C_6$ -C<sub>10</sub>-aryl and alkinoyloxy is  $C_3$ -C<sub>6</sub>-alkinoyloxy;

 $R_5$ : hydrogen; hydroxy;  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_{10}$ -alkyloxyalkoxy, where alkyloxy is  $C_1$ - $C_4$  alkyloxy and alkoxy is  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_6$ -alkenyloxy;  $C_2$ - $C_6$ -alkinyloxy;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyloxy, where alkyl is  $C_1$ - $C_6$  alkyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyloxy, where alkenyl is  $C_2$ - $C_6$  alkenyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyloxy, where alkinyl is  $C_2$ - $C_6$  alkinyl;  $C_7$ - $C_{16}$ -arylalkyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkenyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkanoyloxy;  $C_7$ - $C_{16}$ -arylalkanoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_2$ - $C_6$ -alkanoyloxy;  $C_7$ - $C_{16}$ -arylalkanoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_2$ - $C_6$ -alkanoyloxy;

## X is oxygen;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, CO<sub>2</sub>H, CONH<sub>2</sub>, CO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), CONH(C<sub>1</sub>-C<sub>3</sub>-alkyl), CON(C<sub>1</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, CO(C<sub>1</sub>-C<sub>3</sub>-alkyl); amino; (C<sub>1</sub>-C<sub>3</sub>-monoalkyl)amino, (C<sub>1</sub>-C<sub>3</sub>-dialkyl)amino; C<sub>5</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>3</sub>-alkanoyl)amido, SH, SO<sub>3</sub>H, SO<sub>3</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkylthio or C<sub>1</sub>-C<sub>3</sub>-alkanoylthio,

wherein -(cyclical saturated group) is either preferably  $C_3$ - $C_{10}$ -cycloalkyl or a heterocyclic group with 2 to 9 carbon atoms, containing further one or more heteroatoms,

with the exception of compounds where  $R_1$  is methyl,  $R_2$  is  $C_4$ - $C_6$ -alkyl,  $R_3$  is hydrogen or methyl,  $R_4$  is hydroxy or methoxy and  $R_5$  is hydroxy, methoxy or an oxygen atom bound to the carbon atom in the 5<sup>th</sup> position,

with the further exception of compounds where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is hydrogen or benzyloxy and  $R_5$  is an oxygen atom bound to the carbon atom in the  $5^{th}$  position; and

with the further exception of compounds where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is hydrogen, hydroxy or benzyloxy and  $R_5$  is hydroxy or methoxy.

2. (Currently Amended) Compounds A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (IA) or (IAa), and/or a pharmaceutically acceptable acid addition salt therof,

where the substituents have the following significance:

 $R_1$ :  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryland alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryland alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryland alkinyl is  $C_2$ - $C_8$ -alkinyl;

wherein the two substituents R<sub>1</sub> can be the same or different;

R<sub>2</sub>: [[C<sub>1</sub>-C<sub>6</sub>-alkyl]]  $\underline{C_2}$ -alkyl,  $\underline{C_3}$ -alkyl,  $\underline{C_4}$ -alkyl,  $\underline{C_5}$ -alkyl or  $\underline{C_6}$ -alkyl;  $\underline{C_2}$ -C<sub>6</sub>-alkenyl;  $\underline{C_2}$ -C<sub>6</sub>-alkenyl;  $\underline{C_2}$ -C<sub>6</sub>-alkenyl;  $\underline{C_3}$ -C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is  $\underline{C_1}$ -C<sub>6</sub>;  $\underline{C_4}$ -C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is  $\underline{C_2}$ -C<sub>6</sub>;  $\underline{C_7}$ -C<sub>16</sub>-arylalkyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkyl is  $\underline{C_1}$ -C<sub>6</sub>-alkyl;  $\underline{C_8}$ -C<sub>16</sub>-arylalkenyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkenyl is  $\underline{C_2}$ -C<sub>6</sub>-alkenyl;  $\underline{C_8}$ -C<sub>16</sub>-arylalkinyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkinyl is  $\underline{C_2}$ -C<sub>6</sub>-alkinyl;  $\underline{C_3}$ -C<sub>6</sub>-alkenyl;  $\underline{C_3}$ -C<sub>6</sub>-alkinoyl;  $\underline{C_9}$ -C<sub>16</sub>-arylalkenoyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkenyl is  $\underline{C_3}$ -C<sub>6</sub>-alkenoyl;  $\underline{C_9}$ -C<sub>16</sub>-arylalkinoyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkenyl is  $\underline{C_3}$ -C<sub>6</sub>-alkenoyl;  $\underline{C_9}$ -C<sub>16</sub>-arylalkinoyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkenyl is  $\underline{C_3}$ -C<sub>6</sub>-alkenoyl;  $\underline{C_9}$ -C<sub>16</sub>-arylalkinoyl, where aryl is  $\underline{C_6}$ -C<sub>10</sub>-aryl and alkenyl is  $\underline{C_3}$ -C<sub>6</sub>-alkinoyl;

 $R_3$ : hydrogen,  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl; alkoxyalkyl, where alkoxy is  $C_1$ - $C_6$ -alkoxy and alkyl is  $C_1$ - $C_6$ -alkyl;  $CO_2$ ( $C_1$ - $C_6$ -alkyl);  $CO_2$ H;  $CH_2$ OH.

R<sub>4</sub>: hydrogen; hydroxy;  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_{10}$ -alkyloxyalkoxy, where alkyloxy is  $C_1$ - $C_4$  alkyloxyl and alkoxy is  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_6$ -alkenyloxy;  $C_2$ - $C_6$ -alkinyloxy;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyloxy, where alkyl is  $C_1$ - $C_6$  alkyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyloxy, where alkenyl is  $C_2$ - $C_6$  alkenyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyloxy where alkinyl is  $C_2$ - $C_6$  alkinyl;  $C_7$ - $C_{16}$ -arylalkyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkanoyloxy;  $C_3$ - $C_6$ -alkenyloxy; where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_3$ - $C_6$ -alkanoyloxy;  $C_9$ - $C_{16}$ -arylalkenoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_3$ - $C_6$ -alkanoyloxy;  $C_9$ - $C_{16}$ -arylalkenoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_3$ - $C_6$ -alkenoyloxy;  $C_9$ - $C_{16}$ -arylalkinoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinoyloxy is  $C_3$ - $C_6$ -alkinoyloxy;  $C_9$ - $C_{16}$ -arylalkinoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinoyloxy is  $C_3$ - $C_6$ -alkinoyloxy;  $C_9$ - $C_{16}$ -arylalkinoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinoyloxy is  $C_3$ - $C_6$ -alkinoyloxy;

 $R_5$ : hydrogen; hydroxy;  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_{10}$ -alkyloxyalkoxy, where alkyloxy is  $C_1$ - $C_4$  alkyloxy and alkoxy is  $C_1$ - $C_6$ -alkyloxy;  $C_2$ - $C_6$ -alkenyloxy;  $C_2$ - $C_6$ -alkinyloxy;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyloxy, where alkyl is  $C_1$ - $C_6$  alkyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyloxy, where alkenyl is  $C_2$ - $C_6$  alkenyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyloxy, where alkinyl is  $C_2$ - $C_6$  alkinyl;  $C_7$ - $C_{16}$ -arylalkyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkenyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkanoyloxy;  $C_7$ - $C_{16}$ -arylalkanoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_2$ - $C_6$ -alkanoyloxy;  $C_7$ - $C_{16}$ -arylalkanoyloxy, where aryl is  $C_6$ - $C_{10}$ -aryl and alkanoyloxy is  $C_2$ - $C_6$ -alkanoyloxy;

## X is oxygen;

Y is I', Br', Cl', OH' or another pharmacologically acceptable counterion;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, CO<sub>2</sub>H, CONH<sub>2</sub>, CO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), CONH(C<sub>1</sub>-C<sub>3</sub>-alkyl), CON(C<sub>1</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, CO(C<sub>1</sub>-C<sub>3</sub>-alkyl); amino; (C<sub>1</sub>-C<sub>3</sub>-monoalkyl)amino, (C<sub>1</sub>-C<sub>3</sub>-dialkyl)amino; C<sub>5</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>3</sub>-alkanoyl)amido, SH, SO<sub>3</sub>H, SO<sub>3</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkylthio or C<sub>1</sub>-C<sub>3</sub>-alkanoylthio, wherein -(cyclical saturated group) is either preferably C<sub>3</sub>-C<sub>10</sub>-cycloalkyl or a heterocyclical group with 2 to 9 carbon atoms, containing furthermore one or more heteroatoms.

3. (Currently Amended) Compounds A composition of claim 1 or 2, wherein for the compound of the formulae formula (I) or (IA), of Claims-1 or 2, wherein  $R_1$  is  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_4$ - $C_{16}$ -cycloalkylalkyl, where cycloalkyl is  $C_3$ - $C_{10}$  cycloalkyl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $R_2$  is [[ $C_7$ - $C_{16}$ -arylalkyl]]  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl; [[ $C_8$ - $C_{16}$ -arylalkenyl]]  $C_8$ -arylalkenyl or  $C_{10}$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $R_3$  is hydrogen or methyl;  $R_4$  is hydroxy, methoxy or acetoxy.

- 4. (Currently Amended) Compounds of A composition of claim 2, wherein for the compound of the formula (IA), of Claim 2, wherein  $R_1$  is  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_4$ - $C_{16}$ -cycloalkylalkyl, where cycloalkyl is  $C_3$ - $C_{10}$  cycloalkyl and alkyl is  $C_1$ - $C_6$  alkyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $R_2$  is [[ $C_1$ - $C_6$ -alkyl]]  $C_2$ - $C_6$ -alkyl or  $C_2$ - $C_6$ -alkenyl,  $R_3$  is hydrogen or methyl;  $R_4$  is hydroxy, methoxy or acetoxy.
- 5. (Currently Amended) A composition of claim 1 or 2, wherein the compound is Compounds of Claims 1 or 2, selected from:

17-allyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-methoxy-5βmethyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-methoxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-hydroxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5\alpha-epoxy-3-methoxy-5\beta-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-hydroxy-5βmethyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5αepoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 4,5α-epoxy-3-methoxy- $5\beta$ , 17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy)morphinan-6-one, 4, 5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ , 17dimethyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-propyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5α-epoxy-3-hydroxy-14β-(3-

phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3phenylpropyloxy)morphinan-6-one, 17-propyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-methoxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-hydroxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-hydroxy-5βmethyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-hydroxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-14β-(3phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(2methylbenzyl)oxy]morphinan-6-one, 14β-[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5αepoxy-3-hydroxymorphinan-6-one, 14β-benzyloxy-17-cyclopropylmethyl-4,5α-epoxy-3hydroxymorphinan-6-one, 14β-butoxy-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxymorphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-methylbutyl)oxy]morphinan-6-one,  $4.5\alpha$ -epoxy- $5\beta.17$ -dimethyl- $14\beta$ -[(3-phenylpropyl)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-one, 14β-[(3-chlorobenzyl)oxy]-4,5α-epoxy-17-methyl-3-[(prop-2-inyl)oxy]morphinan-6-one, 4,5αepoxy-17-ethyl-3-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-17-ethyl-3hydroxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-3-hydroxy-14β-[(3-

methylbutyl)oxy]-17-propylmorphinan-6-one, 5β-benzyl-14-methoxycodeinone (= 5-benzyl-7,8didehydro-4,5α-epoxy-3,14β-dimethoxy-17-methyl-morphinan-6-one), 5β-benzyl-4,5α-epoxy-3,14β-dimethoxy-17-methylmorphinan-6-one, 5β-benzyl-4,5α-epoxy-3-hydoxy-14β-methoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]morphinan-6-one, 3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxyl-morphinan-6-one, 14βbenzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one, 14\beta-benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14β-[(2naphthylmethyl)oxylmorphinan-6-one, 3,4-dimethoxy-17-methyl-14B-[(2-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-5\(\beta\),17-dimethyl-14\(\beta\)-[(3phenylpropyl)oxyl-morphinan-6-one, 14β-ethoxy-4-hydroxy-3-methoxy-5β,17dimethylmorphinan-6-one, 14\beta-ethoxy-3,4-dimethoxy-5\beta,17-dimethylmorphinan-6-one, 14\beta-ethoxy-3,4-dimethylmorphinan-6-one, 14\beta-ethoxy-3,4-di benzyloxy-3,4-dimethoxy-5β,17-dimethylmorphinan-6-one, 4,5α-epoxy-3-hydroxy-17,17dimethyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17S)-4,5α-epoxy-17-ethyl-3hydroxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-4,5α-epoxy-3-hydroxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofurfuran-2yl)methyl]morphinanium-iodide, (17R)-17-allyl-4,5 $\alpha$ -epoxy-14 $\beta$ -ethoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide, (17R)-17-allyl-4,5α-epoxy 3-hydroxy-14β-methoxy-17-methyl-6oxomorphinanium-iodide, (17S)-17-allyl-4,5α-epoxy-3-hydroxy-14β-methoxy-17-methyl-6oxomorphinanium-iodide, 4,5α-epoxy-3-hydroxy-14β-methoxy-17,17-dimethyl-6-oxomorphinanium-iodide, 5β-benzyl-14β-(butyloxy)-4,5-epoxy-3-hydroxy-17,17-dimethyl-6oxomorphinanium-iodide, (17S)-17-allyl-5β-benzyl-14β-butoxy-4,5α-epoxy-3-hydroxy-17methyl-6-oxomorphinanium-iodide, 14β-butoxy-4,5α-epoxy-3-hydroxy-17,17-dimethyl-6-

oxomorphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-17-methyl-6oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5α-epoxy-3-methoxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17cyclopropylmethyl-4,5α-epoxy-3-hydroxy-17-methyl-6-oxo-14β-[(2phenylbenzyl)oxylmorphinanium-iodide, (17R)-14β-[(4-chlorobenzyl)oxy]-17cyclopropylmethyl-4,5\alpha-epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide, 17(R)-4,5\alphaepoxy-3-hydroxy-14β-methoxy-17-methyl-6-oxo-17-(2-phenylethyl)morphinanium-iodide, 4,5αexpoxy-3-methoxy-17-methyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one,  $4,5\alpha$ -expoxy-3-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  $4.5\alpha$ -expoxy-3-hydroxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  $4.5\alpha$ -expoxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4,5α-epoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one,  $4.5\alpha$ -epoxy- $14\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4-(n-butyloxy)-17-(cyclopropylmethyl)-14β-[(3-phenylpropyl)oxy]morphinan-6-one, and a pharmaceutically acceptable salt thereof.

Claim 6. (Cancelled)

Claim 7. (Cancelled).

- 8. (Currently Amended) A method of treating pain, comprising the step of administering to a patient in need thereof an effective amount of the compound composition of claim 1 or 2.
- 9. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound,  $R_5$  is OH or alkyloxy.
- 10. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound, R<sub>3</sub> is hydrogen, alkyl or aralkyl, preferably hydrogen or alkyl.
- 11. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound, R<sub>4</sub> is OH, alkyloxy, or alkinyloxy.
- 12. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound, a single bond is present between the carbon atoms of the numbers 7 and 8.
- 13. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound, R<sub>2</sub> is alkyl or aralkyl, preferably aralkyl.
- 14. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound, R<sub>1</sub> is alkyl, (cyclical saturated group)alkyl, aralkyl or alkenyl.

- 15. (Currently Amended) Compounds A composition according to Claim 1 or 2, wherein in the compound,  $R_1$  is  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$  alkyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$  alkenyl;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$  alkinyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkinyl.
- 16. (New) A composition according to claim 10, wherein in the compound, R<sub>3</sub> is hydrogen or alkyl.
- 17. (New) A composition according to claim 13, wherein in the compound,  $R_2$  is aralkyl.